ID   SIK3_HUMAN              Reviewed;        1321 AA.
AC   Q9Y2K2; A1A5A8; H0Y494; J3KPC8; Q59FY2; Q5M9N1; Q6P3R6; Q8IYM8; Q9HA50;
DT   03-OCT-2006, integrated into UniProtKB/Swiss-Prot.
DT   28-MAR-2018, sequence version 4.
DT   12-OCT-2022, entry version 175.
DE   RecName: Full=Serine/threonine-protein kinase SIK3 {ECO:0000305};
DE            EC=2.7.11.1 {ECO:0000269|PubMed:29211348};
DE   AltName: Full=Salt-inducible kinase 3;
DE            Short=SIK-3;
DE   AltName: Full=Serine/threonine-protein kinase QSK;
GN   Name=SIK3 {ECO:0000312|HGNC:HGNC:29165};
GN   Synonyms=KIAA0999 {ECO:0000303|PubMed:10231032}, QSK
GN   {ECO:0000303|PubMed:14976552}; ORFNames=L19;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, ACTIVITY REGULATION, PHOSPHORYLATION
RP   AT THR-221, AND MUTAGENESIS OF THR-221.
RX   PubMed=14976552; DOI=10.1038/sj.emboj.7600110;
RA   Lizcano J.M., Goeransson O., Toth R., Deak M., Morrice N.A., Boudeau J.,
RA   Hawley S.A., Udd L., Maekelae T.P., Hardie D.G., Alessi D.R.;
RT   "LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily,
RT   including MARK/PAR-1.";
RL   EMBO J. 23:833-843(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), NUCLEOTIDE SEQUENCE
RP   [MRNA] OF 47-1321 (ISOFORM 4), NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF
RP   725-1321 (ISOFORM 3), AND NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF
RP   816-1321 (ISOFORM 1).
RC   TISSUE=Testis, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 8-1321 (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=10231032; DOI=10.1093/dnares/6.1.63;
RA   Nagase T., Ishikawa K., Suyama M., Kikuno R., Hirosawa M., Miyajima N.,
RA   Tanaka A., Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XIII. The
RT   complete sequences of 100 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 6:63-70(1999).
RN   [5]
RP   SEQUENCE REVISION.
RX   PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 331-1321 (ISOFORM 1), AND VARIANT
RP   ARG-1136.
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 816-1321 (ISOFORM 1).
RC   TISSUE=Mammary gland;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 817-1321 (ISOFORM 1).
RX   PubMed=15334068; DOI=10.1038/sj.onc.1207921;
RA   Petroziello J., Yamane A., Westendorf L., Thompson M., McDonagh C.,
RA   Cerveny C., Law C.-L., Wahl A., Carter P.;
RT   "Suppression subtractive hybridization and expression profiling identifies
RT   a unique set of genes overexpressed in non-small-cell lung cancer.";
RL   Oncogene 23:7734-7745(2004).
RN   [9]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH YWHAZ.
RX   PubMed=16306228; DOI=10.1242/jcs.02670;
RA   Al-Hakim A.K., Goransson O., Deak M., Toth R., Campbell D.G., Morrice N.A.,
RA   Prescott A.R., Alessi D.R.;
RT   "14-3-3 cooperates with LKB1 to regulate the activity and localization of
RT   QSK and SIK.";
RL   J. Cell Sci. 118:5661-5673(2005).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-626, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-71; THR-221; SER-551; SER-626
RP   AND SER-866, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-113 (ISOFORM 2), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-221; THR-469; SER-551;
RP   SER-626 AND SER-866, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-469; SER-626 AND SER-978, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [15]
RP   FUNCTION, INTERACTION WITH 14-3-3 PROTEINS, PTM, AND MUTAGENESIS OF
RP   THR-469; SER-551 AND SER-626.
RX   PubMed=29211348; DOI=10.1111/febs.14351;
RA   Sonntag T., Vaughan J.M., Montminy M.;
RT   "14-3-3 proteins mediate inhibitory effects of cAMP on salt-inducible
RT   kinases (SIKs).";
RL   FEBS J. 285:467-480(2018).
RN   [16]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-389 AND VAL-1161.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [17]
RP   INVOLVEMENT IN SEMDK, VARIANT SEMDK CYS-187, CHARACTERIZATION OF VARIANT
RP   SEMDK CYS-187, FUNCTION, INTERACTION WITH DEPTOR; MLST8; RICTOR AND RPTOR,
RP   CATALYTIC ACTIVITY, TISSUE SPECIFICITY, AND PHOSPHORYLATION AT THR-221.
RX   PubMed=30232230; DOI=10.1126/scitranslmed.aat9356;
RA   Csukasi F., Duran I., Barad M., Barta T., Gudernova I., Trantirek L.,
RA   Martin J.H., Kuo C.Y., Woods J., Lee H., Cohn D.H., Krejci P., Krakow D.;
RT   "The PTH/PTHrP-SIK3 pathway affects skeletogenesis through altered mTOR
RT   signaling.";
RL   Sci. Transl. Med. 10:0-0(2018).
CC   -!- FUNCTION: Positive regulator of mTOR signaling that functions by
CC       triggering the degradation of DEPTOR, an mTOR inhibitor. Involved in
CC       the dynamic regulation of mTOR signaling in chondrocyte differentiation
CC       during skeletogenesis (PubMed:30232230). Negatively regulates cAMP
CC       signaling pathway possibly by acting on CRTC2/TORC2 and CRTC3/TORC3
CC       (Probable). Prevents HDAC4 translocation to the nucleus (By
CC       similarity). {ECO:0000250|UniProtKB:Q6P4S6,
CC       ECO:0000269|PubMed:30232230, ECO:0000305|PubMed:29211348}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:30232230};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:30232230};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000250|UniProtKB:Q9H0K1};
CC   -!- ACTIVITY REGULATION: Activated by phosphorylation on Thr-221.
CC       {ECO:0000250|UniProtKB:Q9H0K1}.
CC   -!- SUBUNIT: Binds to and is activated by YWHAZ when phosphorylated on Thr-
CC       221 (PubMed:16306228). Interacts with 14-3-3 proteins
CC       (PubMed:29211348). Interacts with HDAC4; this interaction leads to
CC       HDAC4 retention in the cytoplasm (By similarity). Interacts with
CC       DEPTOR, MLST8/GbetaL, RICTOR and RPTOR (PubMed:30232230).
CC       {ECO:0000250|UniProtKB:Q6P4S6, ECO:0000269|PubMed:16306228,
CC       ECO:0000269|PubMed:29211348, ECO:0000269|PubMed:30232230}.
CC   -!- INTERACTION:
CC       Q9Y2K2; P63104: YWHAZ; NbExp=5; IntAct=EBI-1181460, EBI-347088;
CC       Q9Y2K2-7; P42858: HTT; NbExp=3; IntAct=EBI-17172855, EBI-466029;
CC       Q9Y2K2-7; Q13077: TRAF1; NbExp=3; IntAct=EBI-17172855, EBI-359224;
CC       Q9Y2K2-7; Q15654: TRIP6; NbExp=3; IntAct=EBI-17172855, EBI-742327;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:16306228}.
CC       Note=Locates to punctate structures within the cytoplasm on binding to
CC       YWHAZ. {ECO:0000269|PubMed:16306228}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q9Y2K2-5; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9Y2K2-6; Sequence=VSP_059412, VSP_059415;
CC       Name=3;
CC         IsoId=Q9Y2K2-7; Sequence=VSP_059416, VSP_059417;
CC       Name=4;
CC         IsoId=Q9Y2K2-8; Sequence=VSP_059413, VSP_059414, VSP_059415;
CC   -!- TISSUE SPECIFICITY: Expressed in chondrocytes.
CC       {ECO:0000269|PubMed:30232230}.
CC   -!- PTM: Phosphorylated at Thr-221 by STK11/LKB1 in complex with STE20-
CC       related adapter-alpha (STRADA) pseudo kinase and CAB39
CC       (PubMed:14976552). Phosphorylation at Thr-221 is inhibited in response
CC       to PTHLH/PTHrP (PubMed:30232230). Phosphorylated at Thr-469 and Ser-551
CC       in response to cAMP signaling (Probable). {ECO:0000269|PubMed:14976552,
CC       ECO:0000269|PubMed:30232230, ECO:0000305|PubMed:29211348}.
CC   -!- DISEASE: Spondyloepimetaphyseal dysplasia, Krakow type (SEMDK)
CC       [MIM:618162]: An autosomal recessive skeletal disorder characterized by
CC       severe spondyloepimetaphyseal dysplasia, rhizomelia, mesomelia with
CC       significant anterior bowing of all limbs, severe immunodeficiency, and
CC       developmental delay. {ECO:0000269|PubMed:30232230}. Note=The disease is
CC       caused by variants affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr
CC       protein kinase family. SNF1 subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH63887.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAI28511.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAA76843.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAB14006.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB023216; BAA76843.2; ALT_INIT; mRNA.
DR   EMBL; AP000936; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP003070; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP006216; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC035583; AAH35583.3; -; mRNA.
DR   EMBL; BC063887; AAH63887.1; ALT_INIT; mRNA.
DR   EMBL; BC086858; AAH86858.1; -; mRNA.
DR   EMBL; BC128510; AAI28511.1; ALT_INIT; mRNA.
DR   EMBL; AB209327; BAD92564.1; -; mRNA.
DR   EMBL; AK022302; BAB14006.1; ALT_INIT; mRNA.
DR   EMBL; AY598338; AAT06749.1; -; mRNA.
DR   CCDS; CCDS60974.1; -. [Q9Y2K2-8]
DR   CCDS; CCDS8379.2; -. [Q9Y2K2-5]
DR   RefSeq; NP_001268678.1; NM_001281749.1. [Q9Y2K2-8]
DR   RefSeq; NP_079440.3; NM_025164.4. [Q9Y2K2-5]
DR   AlphaFoldDB; Q9Y2K2; -.
DR   SMR; Q9Y2K2; -.
DR   BioGRID; 116963; 36.
DR   IntAct; Q9Y2K2; 45.
DR   MINT; Q9Y2K2; -.
DR   STRING; 9606.ENSP00000364449; -.
DR   BindingDB; Q9Y2K2; -.
DR   ChEMBL; CHEMBL6149; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; Q9Y2K2; -.
DR   GuidetoPHARMACOLOGY; 2199; -.
DR   iPTMnet; Q9Y2K2; -.
DR   PhosphoSitePlus; Q9Y2K2; -.
DR   BioMuta; SIK3; -.
DR   DMDM; 115502238; -.
DR   EPD; Q9Y2K2; -.
DR   jPOST; Q9Y2K2; -.
DR   MassIVE; Q9Y2K2; -.
DR   MaxQB; Q9Y2K2; -.
DR   PaxDb; Q9Y2K2; -.
DR   PeptideAtlas; Q9Y2K2; -.
DR   PRIDE; Q9Y2K2; -.
DR   ProteomicsDB; 108; -.
DR   ProteomicsDB; 34706; -.
DR   ABCD; Q9Y2K2; 6 sequenced antibodies.
DR   Antibodypedia; 56803; 166 antibodies from 26 providers.
DR   DNASU; 23387; -.
DR   Ensembl; ENST00000375300.6; ENSP00000364449.1; ENSG00000160584.17. [Q9Y2K2-5]
DR   Ensembl; ENST00000446921.6; ENSP00000390442.2; ENSG00000160584.17. [Q9Y2K2-8]
DR   GeneID; 23387; -.
DR   KEGG; hsa:23387; -.
DR   CTD; 23387; -.
DR   DisGeNET; 23387; -.
DR   GeneCards; SIK3; -.
DR   HGNC; HGNC:29165; SIK3.
DR   HPA; ENSG00000160584; Low tissue specificity.
DR   MalaCards; SIK3; -.
DR   MIM; 614776; gene.
DR   MIM; 618162; phenotype.
DR   neXtProt; NX_Q9Y2K2; -.
DR   OpenTargets; ENSG00000160584; -.
DR   PharmGKB; PA165543631; -.
DR   VEuPathDB; HostDB:ENSG00000160584; -.
DR   eggNOG; KOG0586; Eukaryota.
DR   GeneTree; ENSGT00940000157259; -.
DR   InParanoid; Q9Y2K2; -.
DR   OMA; CQQLKED; -.
DR   OrthoDB; 1127668at2759; -.
DR   PhylomeDB; Q9Y2K2; -.
DR   TreeFam; TF315213; -.
DR   PathwayCommons; Q9Y2K2; -.
DR   SignaLink; Q9Y2K2; -.
DR   SIGNOR; Q9Y2K2; -.
DR   BioGRID-ORCS; 23387; 23 hits in 1008 CRISPR screens.
DR   ChiTaRS; SIK3; human.
DR   GeneWiki; KIAA0999; -.
DR   GenomeRNAi; 23387; -.
DR   Pharos; Q9Y2K2; Tchem.
DR   PRO; PR:Q9Y2K2; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; Q9Y2K2; protein.
DR   Bgee; ENSG00000160584; Expressed in lateral globus pallidus and 206 other tissues.
DR   ExpressionAtlas; Q9Y2K2; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0050321; F:tau-protein kinase activity; IBA:GO_Central.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0000226; P:microtubule cytoskeleton organization; IBA:GO_Central.
DR   GO; GO:1904263; P:positive regulation of TORC1 signaling; IMP:UniProtKB.
DR   GO; GO:1904515; P:positive regulation of TORC2 signaling; IMP:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   CDD; cd14071; STKc_SIK; 1.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR034672; SIK.
DR   InterPro; IPR015940; UBA.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS50030; UBA; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Cytoplasm; Disease variant; Dwarfism;
KW   Kinase; Magnesium; Metal-binding; Methylation; Nucleotide-binding;
KW   Phosphoprotein; Reference proteome; Serine/threonine-protein kinase;
KW   Transferase.
FT   CHAIN           1..1321
FT                   /note="Serine/threonine-protein kinase SIK3"
FT                   /id="PRO_0000252257"
FT   DOMAIN          66..317
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          344..384
FT                   /note="UBA"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00212"
FT   REGION          1..59
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          585..614
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          727..772
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          894..945
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1256..1289
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        597..614
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        740..772
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        897..916
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        188
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         72..80
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         95
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         71
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         221
FT                   /note="Phosphothreonine; by LKB1"
FT                   /evidence="ECO:0000269|PubMed:14976552,
FT                   ECO:0000269|PubMed:30232230, ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         469
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:29211348,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         551
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         591
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q6P4S6"
FT   MOD_RES         592
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q6P4S6"
FT   MOD_RES         626
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         647
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q6P4S6"
FT   MOD_RES         866
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         978
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         986
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q6P4S6"
FT   VAR_SEQ         1..760
FT                   /note="MAAAAASGAGGAAGAGTGGAGPAGRLLPPPAPGSPAAPAAVSPAAGQPRPPA
FT                   PASRGPMPARIGYYEIDRTIGKGNFAVVKRATHLVTKAKVAIKIIDKTQLDEENLKKIF
FT                   REVQIMKMLCHPHIIRLYQVMETERMIYLVTEYASGGEIFDHLVAHGRMAEKEARRKFK
FT                   QIVTAVYFCHCRNIVHRDLKAENLLLDANLNIKIADFGFSNLFTPGQLLKTWCGSPPYA
FT                   APELFEGKEYDGPKVDIWSLGVVLYVLVCGALPFDGSTLQNLRARVLSGKFRIPFFMST
FT                   ECEHLIRHMLVLDPNKRLSMEQICKHKWMKLGDADPNFDRLIAECQQLKEERQVDPLNE
FT                   DVLLAMEDMGLDKEQTLQSLRSDAYDHYSAIYSLLCDRHKRHKTLRLGALPSMPRALAF
FT                   QAPVNIQAEQAGTAMNISVPQVQLINPENQIVEPDGTLNLDSDEGEEPSPEALVRYLSM
FT                   RRHTVGVADPRTEVMEDLQKLLPGFPGVNPQAPFLQVAPNVNFMHNLLPMQNLQPTGQL
FT                   EYKEQSLLQPPTLQLLNGMGPLGRRASDGGANIQLHAQQLLKRPRGPSPLVTMTPAVPA
FT                   VTPVDEESSDGEPDQEAVQSSTYKDSNTLHLPTERFSPVRRFSDGAASIQAFKAHLEKM
FT                   GNNSSIKQLQQECEQLQKMYGGQIDERTLEKTQQQHMLYQQEQHHQILQQQIQDSICPP
FT                   QPSPPLQAACENQPALLTHQLQRLRIQPSSPPPNHPNNHLFRQPSNSPPPMSSAMIQPH
FT                   -> MACSTPHGSNRRLPRKCHFSLPTRTPTLCTSLRSVSPLCAGSQMGLRASRPSKLTW
FT                   KKWATTAASNSCSRSVSSCRRCTGGRLMKEPWRRPSSSICYTSRSSTIKFSSNKFKTLS
FT                   VLLSHLHLFRLHVKISQPSLPISSR (in isoform 2)"
FT                   /id="VSP_059412"
FT   VAR_SEQ         365..412
FT                   /note="Missing (in isoform 4)"
FT                   /id="VSP_059413"
FT   VAR_SEQ         603
FT                   /note="S -> RYLANRSKRHTLAMTNPTAEIPPDLQRQLGQQPFRSRVWPPHLVPDQ
FT                   HR (in isoform 4)"
FT                   /id="VSP_059414"
FT   VAR_SEQ         874..933
FT                   /note="Missing (in isoform 2 and isoform 4)"
FT                   /id="VSP_059415"
FT   VAR_SEQ         1171..1187
FT                   /note="EPVIGNCMDRSSPGQAV -> GKCLLTVEVLGQSALIN (in isoform
FT                   3)"
FT                   /id="VSP_059416"
FT   VAR_SEQ         1188..1321
FT                   /note="Missing (in isoform 3)"
FT                   /id="VSP_059417"
FT   VARIANT         187
FT                   /note="R -> C (in SEMDK; decreased protein expression;
FT                   decreased kinase activity; no effect on the interaction
FT                   with DEPTOR, MLST8/GbetaL, RICTOR and RPTOR;
FT                   dbSNP:rs1565460853)"
FT                   /evidence="ECO:0000269|PubMed:30232230"
FT                   /id="VAR_081542"
FT   VARIANT         389
FT                   /note="H -> L (in a breast cancer sample; somatic mutation;
FT                   dbSNP:rs376144593)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_035634"
FT   VARIANT         1098
FT                   /note="D -> E (in dbSNP:rs11216163)"
FT                   /id="VAR_051662"
FT   VARIANT         1136
FT                   /note="P -> R (in dbSNP:rs12225230)"
FT                   /evidence="ECO:0000269|Ref.6"
FT                   /id="VAR_051663"
FT   VARIANT         1161
FT                   /note="A -> V (in a breast cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_035635"
FT   MUTAGEN         221
FT                   /note="T->A: Prevents phosphorylation and activation by
FT                   STK11/LKB1 complex."
FT                   /evidence="ECO:0000269|PubMed:14976552"
FT   MUTAGEN         469
FT                   /note="T->A: Loss of interaction with 14-3-3 proteins in
FT                   response to cAMP signaling; inhibits cAMP signaling."
FT                   /evidence="ECO:0000269|PubMed:29211348"
FT   MUTAGEN         469
FT                   /note="T->E: Loss of interaction with 14-3-3 proteins in
FT                   response to cAMP signaling; inhibits cAMP signaling."
FT                   /evidence="ECO:0000269|PubMed:29211348"
FT   MUTAGEN         551
FT                   /note="S->A: Loss of interaction with 14-3-3 proteins in
FT                   response to cAMP signaling; inhibits cAMP signaling."
FT                   /evidence="ECO:0000269|PubMed:29211348"
FT   MUTAGEN         551
FT                   /note="S->E: Loss of interaction with 14-3-3 proteins in
FT                   response to cAMP signaling; inhibits cAMP signaling."
FT                   /evidence="ECO:0000269|PubMed:29211348"
FT   MUTAGEN         626
FT                   /note="S->A: No effect on interaction with 14-3-3 proteins,
FT                   nor on cAMP signaling."
FT                   /evidence="ECO:0000269|PubMed:29211348"
FT   MUTAGEN         626
FT                   /note="S->E: No effect on cAMP signaling."
FT                   /evidence="ECO:0000269|PubMed:29211348"
FT   MOD_RES         Q9Y2K2-6:113
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
SQ   SEQUENCE   1321 AA;  144851 MW;  84FA57F6BB5505DA CRC64;
     MAAAAASGAG GAAGAGTGGA GPAGRLLPPP APGSPAAPAA VSPAAGQPRP PAPASRGPMP
     ARIGYYEIDR TIGKGNFAVV KRATHLVTKA KVAIKIIDKT QLDEENLKKI FREVQIMKML
     CHPHIIRLYQ VMETERMIYL VTEYASGGEI FDHLVAHGRM AEKEARRKFK QIVTAVYFCH
     CRNIVHRDLK AENLLLDANL NIKIADFGFS NLFTPGQLLK TWCGSPPYAA PELFEGKEYD
     GPKVDIWSLG VVLYVLVCGA LPFDGSTLQN LRARVLSGKF RIPFFMSTEC EHLIRHMLVL
     DPNKRLSMEQ ICKHKWMKLG DADPNFDRLI AECQQLKEER QVDPLNEDVL LAMEDMGLDK
     EQTLQSLRSD AYDHYSAIYS LLCDRHKRHK TLRLGALPSM PRALAFQAPV NIQAEQAGTA
     MNISVPQVQL INPENQIVEP DGTLNLDSDE GEEPSPEALV RYLSMRRHTV GVADPRTEVM
     EDLQKLLPGF PGVNPQAPFL QVAPNVNFMH NLLPMQNLQP TGQLEYKEQS LLQPPTLQLL
     NGMGPLGRRA SDGGANIQLH AQQLLKRPRG PSPLVTMTPA VPAVTPVDEE SSDGEPDQEA
     VQSSTYKDSN TLHLPTERFS PVRRFSDGAA SIQAFKAHLE KMGNNSSIKQ LQQECEQLQK
     MYGGQIDERT LEKTQQQHML YQQEQHHQIL QQQIQDSICP PQPSPPLQAA CENQPALLTH
     QLQRLRIQPS SPPPNHPNNH LFRQPSNSPP PMSSAMIQPH GAASSSQFQG LPSRSAIFQQ
     QPENCSSPPN VALTCLGMQQ PAQSQQVTIQ VQEPVDMLSN MPGTAAGSSG RGISISPSAG
     QMQMQHRTNL MATLSYGHRP LSKQLSADSA EAHSLNVNRF SPANYDQAHL HPHLFSDQSR
     GSPSSYSPST GVGFSPTQAL KVPPLDQFPT FPPSAHQQPP HYTTSALQQA LLSPTPPDYT
     RHQQVPHILQ GLLSPRHSLT GHSDIRLPPT EFAQLIKRQQ QQRQQQQQQQ QQQEYQELFR
     HMNQGDAGSL APSLGGQSMT ERQALSYQNA DSYHHHTSPQ HLLQIRAQEC VSQASSPTPP
     HGYAHQPALM HSESMEEDCS CEGAKDGFQD SKSSSTLTKG CHDSPLLLST GGPGDPESLL
     GTVSHAQELG IHPYGHQPTA AFSKNKVPSR EPVIGNCMDR SSPGQAVELP DHNGLGYPAR
     PSVHEHHRPR ALQRHHTIQN SDDAYVQLDN LPGMSLVAGK ALSSARMSDA VLSQSSLMGS
     QQFQDGENEE CGASLGGHEH PDLSDGSQHL NSSCYPSTCI TDILLSYKHP EVSFSMEQAG
     V
//
